Nuvaira, Inc. is a biotechnology and medical devices startup with the slogan "Our dNerva® Lung Denervation System is an investigative COPD therapy that aims to preserve patient lung health." Founded in 2008, the company is headquartered in Minneapolis, Minnesota USA. Nuvaira focuses on developing innovative therapies for obstructive lung disease, with a particular emphasis on addressing clinical needs in the treatment of overactive airway nerves prevalent in both COPD and asthma.
The company has a strong intellectual property portfolio, with more than 75 patents issued and pending worldwide. Its flagship product, the dNerva® Lung Denervation System, has received CE Mark approval and is currently under clinical investigation. However, it is not commercially available in the USA.
The latest investment for Nuvaira, Inc. amounted to $52.88K in a Venture Round investment on 09 May 2024. The identity of the specific investors in this round is not disclosed.
Nuvaira, Inc. is positioned to make a significant impact in the biotechnology and healthcare sectors with its pioneering approach to improving the lives of the more than 65 million people worldwide suffering from obstructive lung disease.
